A tetraspecific engager armed with a non-alpha IL-2 variant harnesses natural killer cells against B cell non-Hodgkin lymphoma | Innate Pharma

Demaria et al, 2024. Science Immunology

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers